Does J9298 require prior authorization?

Yes, J9298 requires prior authorization (high confidence). At least one active policy explicitly requires prior authorization.

What is the Medicare reimbursement rate for J9298?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J9298`, Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

At least one active policy explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Procedure codes listed are for general reference and may not be all-inclusive.
Benefit coverage/reimbursement determinations must be based on the written coverage position in the Medical Policy, not on the presence or absence of listed codes.

Key Coverage Criteria

Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.
Medically necessary when the drug has an NCCN category 1, 2A, or 2B recommendation or is listed in the NCCN Drugs & Biologics Compendium.
Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.
Medically necessary when the drug has an NCCN category 1, 2A, or 2B recommendation or is listed in the NCCN Drugs & Biologics Compendium.
Oncology medications are medically necessary if (a) the drug is FDA-approved for the oncologic indication and used per FDA labeling, OR (b) the drug has an NCCN Category 1/2A/2B indication per NCCN Guidelines or NCCN Compendium.
Oncology medications may be considered medically necessary when the drug (a) is FDA-approved for an oncologic indication and used per FDA labeling, or (b) has NCCN Category 1/2A/2B recommendation per NCCN Guidelines or NCCN Compendium.

18 Active Policies

ARKBLUE-NIVOLUMAB-AND-RELATLIMAB-RMBW-E-G-OPDUALAG-427E834691, Nivolumab and relatlimab-rmbw (e.g., Opdualag)

FLORIDA_BLUE-FLBLUE-NIVOLUMAB-RELATLIMAB-RMBW-OPDUALAG-INJECTION-7B83A217B4, Nivolumab; Relatlimab-rmbw (Opdualag) injection

BCBSM-2163070-F1E74C2002, OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)

POINT32HEALTH-MDMNG-13396, Opdualag (nivolumab and relatlimab-rmbw)

MULTI

POINT32HEALTH-MDMNG-13406, Opdualag (nivolumab and relatlimabrmbw)

MULTI

HEALTHNET_OR-HNOR-NIVOLUMAB-RELATLIMAB-RMBW-OPDUALAG-CP-PHAR-588-DDF361220E, Nivolumab/Relatlimab-rmbw (Opdualag); CP.PHAR.588

MODA-OPDUALAG-B555E05EFB, Opdualag (nivolumab/relatlimab-rmbw)

IBX-MEDICARE-ADVANTAGE-MA08-152D-E5185D50A8, Nivolumab and relatlimab-rmbw (Opdualag) for intravenous use

IBX-COMMERCIAL-08-01-94D-C81FF6DF45, Nivolumab and Relatlimab-rmbw (Opdualag) for intravenous use

BCBSOK-RX502.061, Oncology Medications

EVICORE-HPLAN-HEALTH_PARTNERS_PLANS-4BC80209CCC5, Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List

AMERIHEALTH-COMMERCIAL-08-01-94D-34AA5BC3B7, Nivolumab and Relatlimab-rmbw (Opdualag) for intravenous use

AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-152D-DD68172DDF, Nivolumab and relatlimab-rmbw (Opdualag) for intravenous use

BCBSTN-1d085c9a43, Nivolumab/Relatlimab-rmbw (Opdualag)

BCBSIL-RX502.061, Oncology Medications

BCBSMT-RX502.061, Oncology Medications

BCBSNM-RX502.061, Oncology Medications

EVICORE-HPLAN-CIGNA-729A536F50C8, Q3 - 2026 Cigna MedOnc Master Drug List.pdf

`J9298`, Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

18 Active Policies

Related Codes

Have a follow-up question?

J9298, Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

18 Active Policies

Related Codes

Have a follow-up question?

`J9298`, Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg